The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2026

Filed:

Oct. 15, 2021
Applicant:

Galvanize Therapeutics, Inc., Redwood City, CA (US);

Inventors:

Seth S. Gleiman, Guilford, CT (US);

Nicholas S. Mercer, San Francisco, CA (US);

Timothy J. O'brien, Santa Clara, CA (US);

Jonathan R. Waldstreicher, West Orange, NJ (US);

Kevin J. Taylor, San Mateo, CA (US);

Luis L. Mangual Arbelo, Sunnyvale, CA (US);

Robert E. Neal, Redwood City, CA (US);

William Sanford Krimsky, Forest Hill, MD (US);

Quim Castellvi, Barcelona, ES;

Assignee:

Galvanize Therapeutics, Inc., San Carlos, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 18/14 (2006.01); A61B 18/00 (2006.01); A61B 18/02 (2006.01); A61B 18/12 (2006.01); A61B 18/16 (2006.01);
U.S. Cl.
CPC ...
A61B 18/1492 (2013.01); A61B 18/02 (2013.01); A61B 18/16 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00327 (2013.01); A61B 2018/00351 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/0044 (2013.01); A61B 2018/00488 (2013.01); A61B 2018/00494 (2013.01); A61B 2018/005 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00517 (2013.01); A61B 2018/00559 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/1253 (2013.01);
Abstract

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.


Find Patent Forward Citations

Loading…